| Oleuropein as a Multi-Target Therapeutic for Alzheimer’s: An In Silico Docking Study |
| Paper ID : 1024-ISCH |
| Authors |
|
Ahmed Mohamed Abdelmaguid *1, Ahmed Elshekh2, Youssef H. El-kordy3, Asmaa A. khedr4, Ahmed E. Abdel Moneim5 1Faculty of science, Helwan University 2Department of Chhemistry, Faculty of Science, Helwan University, Cairo, Egyp 3Department of zoology, Faculty of Science, Helwan University, Cairo, Egypt 4Department of zoology and entamology faculty of science, Helwan university, Cairo, Egypt. 5Department of Zoology, Faculty of Science, Helwan University, Cairo, Egypt |
| Abstract |
| Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, oxidative stress, and β-amyloid deposition. Current therapies provide only limited symptomatic relief, emphasizing the urgent need for novel neuroprotective strategies. Oleuropein (OLE), a natural phenolic compound derived from olive leaves, possesses strong antioxidant and anti-inflammatory properties. This study primarily focuses on the in silico molecular docking evaluation of OLE against key AD-related proteins. Molecular docking results revealed significant interactions between OLE and β-amyloid, tau, apolipoprotein E, TREM2, and complement protein C1q. Interestingly, the strongest binding affinity was observed with C1q (–7.5 kcal/mol), suggesting a potential modulatory role in complement-mediated neuroinflammation, while moderate affinities (–5.5 to –6.5 kcal/mol) were observed with the other targets. These findings clearly indicate that OLE may exert multi-target neuroprotective effects by inhibiting protein aggregation, reducing oxidative and inflammatory stress, and modulating complement activation. Such broad-spectrum activity further highlights OLE as a promising natural therapeutic candidate for AD prevention or management. |
| Keywords |
| Alzheimer’s disease Oleuropein Molecular docking β-amyloid Neuroinflammation |
| Status: Abstract Accepted (Poster Presentation) |